Peptides and Adrenal Fatigue: Cortisol and HPA Axis Research

What Is “Adrenal Fatigue”?

Let’s start with the controversy: conventional medicine does not recognize “adrenal fatigue” as a formal diagnosis. Standard endocrinology recognizes adrenal insufficiency (Addison’s disease) — a serious, measurable condition where the adrenal glands literally cannot produce enough cortisol. That’s not what most people mean when they talk about “adrenal fatigue.”

What people typically describe is a cluster of symptoms — persistent exhaustion despite sleep, brain fog, low motivation, difficulty managing stress, and feeling “burned out” — often attributed to overworked adrenal glands. A more scientifically accurate framing is HPA axis dysregulation: a disruption in the hypothalamus-pituitary-adrenal axis, the body’s central stress response system.

HPA axis dysregulation is real and well-documented in the research literature, even if “adrenal fatigue” as a label is contested.

The HPA Axis: Your Stress Response System

The HPA axis is a cascade of communication between three key organs:

• Hypothalamus — detects stress, releases CRH (corticotropin-releasing hormone)
• Pituitary gland — responds to CRH by releasing ACTH (adrenocorticotropic hormone)
• Adrenal glands — respond to ACTH by producing cortisol

Cortisol is the primary stress hormone. In the short term, it helps you respond to threats — raising blood sugar, sharpening focus, suppressing non-urgent body functions. But chronically elevated cortisol wears down the system. Eventually, cortisol rhythms flatten — too high at night, too low in the morning — and you get the “tired but wired” feeling associated with burnout.

Research is investigating whether peptides that modulate this system can help restore normal HPA function.

Selank: Anxiolytic Peptide with HPA Effects

Selank is a synthetic hexapeptide originally developed at the Institute of Molecular Genetics in Moscow. It was designed as an anxiolytic (anti-anxiety) compound with a favorable safety profile compared to benzodiazepines.

Research on Selank has documented:

• Reduction in anxiety-related behaviors in animal stress models
• Modulation of GABAergic and serotonergic pathways — both involved in stress response
• Reduction of pro-inflammatory cytokines associated with chronic stress (IL-6, TNF-α)
• Influence on BDNF (brain-derived neurotrophic factor) — relevant to stress-related neuroplasticity

Selank’s effects on the HPA axis specifically include modulation of CRH sensitivity — potentially helping to normalize the overactivated stress response associated with chronic psychological pressure. In Russian clinical studies, it has been used for anxiety disorders and stress-related conditions.

Selank →

Semax: Cognitive Protection and Stress Resilience

Semax is another synthetic peptide from the same Russian research tradition. Originally developed as a nootropic and neuroprotective agent, Semax is derived from ACTH — the same pituitary hormone involved in the HPA stress cascade.

Interestingly, Semax activates some of the same receptors as ACTH without triggering full cortisol release. Research suggests it may provide some of the cognitive and stress-adaptive benefits of the HPA response without the cortisol burden.

In research models, Semax has shown:

• Neuroprotective effects in oxidative stress conditions
• Enhanced BDNF production — supporting brain resilience
• Improved cognitive performance under stress conditions
• Potential modulation of dopaminergic pathways relevant to motivation and reward

For HPA axis research, Semax is interesting as a potential way to support cognitive function during high-stress periods without further burdening the adrenal system.

Semax →

DSIP: The Sleep and Cortisol Peptide

DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide with documented effects on both sleep architecture and cortisol regulation. In research models, DSIP has shown the ability to:

• Increase slow-wave (deep) sleep duration
• Reduce nocturnal cortisol levels — addressing the “cortisol high at night” pattern of HPA dysregulation
• Normalize disrupted circadian rhythms in stress-affected models
• Exhibit antioxidant properties in stress conditions

If the HPA axis dysregulation is manifesting primarily through disrupted sleep and elevated nighttime cortisol — common presentations — DSIP is one of the more directly relevant peptides being researched.

What the Research Doesn’t Confirm

• No peptide has been approved or clinically validated for “adrenal fatigue” or HPA axis dysregulation.
• Most evidence comes from preclinical models and small Russian clinical studies that require replication in larger Western trials.
• HPA axis dysregulation has many causes — chronic stress, sleep disorders, thyroid dysfunction, autoimmune conditions — and the approach to it should be tailored accordingly.
• Anyone experiencing the symptoms described here should rule out actual adrenal insufficiency and thyroid disorders with proper medical testing first.

Summary of Key Research References

Written by NorthPeptide Research Team